Document Detail

Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial.
MedLine Citation:
PMID:  19789403     Owner:  NLM     Status:  MEDLINE    
AIMS: Hawthorn's efficacy when added to contemporary evidence-based heart failure therapy is unknown. We aimed to determine whether hawthorn increases submaximal exercise capacity when added to standard medical therapy.
METHODS AND RESULTS: We performed a randomized, double-blind, placebo-controlled trial in 120 ambulatory patients aged > or = 18 years with New York Heart Association (NYHA) class II-III chronic heart failure. All patients received conventional medical therapy, as tolerated, and were randomized to either hawthorn 450 mg twice daily or placebo for 6 months. The primary outcome was change in 6 min walk distance at 6 months. Secondary outcomes included quality of life (QOL) measures, peak oxygen consumption, and anaerobic threshold during maximal treadmill exercise testing, NYHA classification, left ventricular ejection fraction (LVEF), neurohormones, and measures of oxidative stress and inflammation. There were no significant differences between groups in the change in 6 min walk distance (P = 0.61), or on measures of QOL, functional capacity, neurohormones, oxidative stress, or inflammation. A modest difference in LVEF favoured hawthorn (P = 0.04). There were significantly more adverse events reported in the hawthorn group (P = 0.02), although most were non-cardiac.
CONCLUSION: Hawthorn provides no symptomatic or functional benefit when given with standard medical therapy to patients with heart failure. This trial is registered in ID: NCT00343902.
Suzanna M Zick; Bonnie Motyka Vautaw; Brenda Gillespie; Keith D Aaronson
Related Documents :
19163283 - A robust control design for heart rate tracking during exercise.
8772743 - Exercise-induced vasodilation in forearm circulation of normal subjects and patients wi...
18550943 - The effect of short-term vertimax vs. depth jump training on vertical jump performance.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural    
Journal Detail:
Title:  European journal of heart failure     Volume:  11     ISSN:  1879-0844     ISO Abbreviation:  Eur. J. Heart Fail.     Publication Date:  2009 Oct 
Date Detail:
Created Date:  2009-09-30     Completed Date:  2010-01-11     Revised Date:  2013-05-31    
Medline Journal Info:
Nlm Unique ID:  100887595     Medline TA:  Eur J Heart Fail     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  990-9     Citation Subset:  IM    
Department of Family Medicine, University of Michigan, Ann Arbor, MI 48109-0708, USA.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anaerobic Threshold / drug effects
Chronic Disease
Double-Blind Method
Exercise Tolerance / drug effects*
Follow-Up Studies
Heart Failure / diagnosis,  drug therapy*,  mortality
Middle Aged
Oxygen Consumption / drug effects,  physiology
Phytotherapy / methods*
Plant Preparations / therapeutic use*
Quality of Life
Reference Values
Risk Assessment
Severity of Illness Index
Stroke Volume / drug effects
Survival Rate
Treatment Outcome
Grant Support
M01-RR00042/RR/NCRR NIH HHS; P50 HL 061202 01/HL/NHLBI NIH HHS
Reg. No./Substance:
0/Plant Preparations

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A randomized, double-blind, placebo-controlled study to determine the effects of valsartan on exerci...
Next Document:  Significance of anaemia in patients with advanced heart failure receiving long-term mechanical circu...